Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse Zai Lab

Zai Lab (NASDAQ:ZLAB)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse Zai Lab

Actualités Zai Lab Ltd

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Jeudi 23 Janvier 2025 ( il y a 5 jours) • Business Wire

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Vendredi 17 Janvier 2025 ( il y a 2 semaines) • Business Wire

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Mercredi 15 Janvier 2025 ( il y a 2 semaines) • Business Wire

Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
Vendredi 10 Janvier 2025 ( il y a 3 semaines) • Business Wire

Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
Vendredi 10 Janvier 2025 ( il y a 3 semaines) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Vendredi 3 Janvier 2025 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Vendredi 13 Décembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Zai Lab Announces Participation in Investor Conference in January 2025
Jeudi 12 Décembre 2024 ( il y a 2 mois) • Business Wire

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Lundi 2 Décembre 2024 ( il y a 2 mois) • Business Wire

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
Jeudi 28 Novembre 2024 ( il y a 2 mois) • Business Wire

Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO® (Sulbactam-Durlobactam)
Jeudi 21 Novembre 2024 ( il y a 2 mois) • Business Wire

Zai Lab Announces Anticipated Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Lundi 18 Novembre 2024 ( il y a 2 mois) • Business Wire

Plus d'articles sur Zai Lab Ltd

Pharus Sicav Algo Flex Q...

BNP Paribas Issuance

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales